Astellas, Roche To Develop Integrated Diabetes Self-management Solution With BlueStar

Astellas Pharma Inc. said that it has reached an agreement with Roche Diabetes Care Japan Co., Ltd. for the development and commercialization of Roche Diabetes Care's Accu-Chek Guide Me blood glucose monitoring system with advanced accuracy as a combined medical product with BlueStar.

BlueStar is an FDA-cleared digital health solution for diabetes patients, developed by Welldoc Inc. and is currently marketed in the U.S. and Canada.

Astellas and Welldoc are jointly developing BlueStar in Japan. Astellas said it will aim to obtain regulatory approval and reimbursement as a combined medical product.

The combined medical product solution, which is being developed in Japan, is expected to support patients with managing their diabetes by capturing, storing, and transmitting blood glucose data which is obtained from Roche Diabetes Care's Accu-Chek Guide Me system and track medication, diet, activity and exercise in Welldoc's BlueStar(app).

It is also expected to support patients' diabetes self-management with a unique algorithm designed using AI, and personalized digital coaching messages, focused on building better habits over time.

Astellas said it is responsible for the clinical trials of the combined medical product, which are scheduled to start during 2023.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
GameStop Corp. Wednesday disclosed that its Board of Directors has elected Chairman Ryan Cohen as Executive Chairman, effective immediately. In a filing with the U.S. Securities and Exchange Commission, the video game retailer said its Board on June 5 terminated Matthew Furlong as President and Chief Executive Officer with immediate effect. Shares of Inditex SA were gaining around 6 percent in the morning trading in Spain after the clothing firm that owns Zara reported Wednesday significant growth in its first-quarter profit on higher revenues as well as the absence of a prior year provision. Regarding the second quarter to date, the company said its store and online sales in constant currency between May 1 and June 4 increased 16.. The U.S. Consumer Product Safety Commission or CPSC, along with Golden, Colorado-based Boppy Co., urged consumers to stop using recalled Boppy Newborn Loungers, following reports of more infant deaths. They also asked online marketplaces to stop selling the recalled product. The company in September 2021 had recalled over 3.3 million infant lounging pillows after it was connected with deaths of 8
Follow RTT